[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia.

M RinzivilloD ProsperiF MazzucaL MagiE IannicelliE PilozziG FranchiA LaghiB AnnibaleA SignoreFrancesco Panzuto

Published in: Journal of endocrinological investigation (2020)

Everolimus is a valid therapeutic option for advanced, progressive, well-differentiated NEN, even in patients with positive FDG-PET findings.

Keyphrases